258 related articles for article (PubMed ID: 25472540)
1. Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse.
O'Leary KA; Shea MP; Schuler LA
Adv Exp Med Biol; 2015; 846():201-20. PubMed ID: 25472540
[TBL] [Abstract][Full Text] [Related]
2. Prolactin drives estrogen receptor-alpha-dependent ductal expansion and synergizes with transforming growth factor-alpha to induce mammary tumors in males.
Arendt LM; Schuler LA
Am J Pathol; 2008 Jan; 172(1):194-202. PubMed ID: 18156207
[TBL] [Abstract][Full Text] [Related]
3. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.
Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA
Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249
[TBL] [Abstract][Full Text] [Related]
4. Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERalpha expression.
Arendt LM; Grafwallner-Huseth TL; Schuler LA
Am J Pathol; 2009 Mar; 174(3):1065-74. PubMed ID: 19179608
[TBL] [Abstract][Full Text] [Related]
5. Prolactin Alters the Mammary Epithelial Hierarchy, Increasing Progenitors and Facilitating Ovarian Steroid Action.
O'Leary KA; Shea MP; Salituro S; Blohm CE; Schuler LA
Stem Cell Reports; 2017 Oct; 9(4):1167-1179. PubMed ID: 28919264
[TBL] [Abstract][Full Text] [Related]
6. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes.
Arendt LM; Evans LC; Rugowski DE; Garcia-Barchino MJ; Rui H; Schuler LA
J Endocrinol; 2009 Oct; 203(1):99-110. PubMed ID: 19635758
[TBL] [Abstract][Full Text] [Related]
7. Prolactin synergizes with canonical Wnt signals to drive development of ER+ mammary tumors via activation of the Notch pathway.
O'Leary KA; Rugowski DE; Shea MP; Sullivan R; Moser AR; Schuler LA
Cancer Lett; 2021 Apr; 503():231-239. PubMed ID: 33472091
[TBL] [Abstract][Full Text] [Related]
8. Prolactin promotes mammary pathogenesis independently from cyclin D1.
Asher JM; O'Leary KA; Rugowski DE; Arendt LM; Schuler LA
Am J Pathol; 2012 Jul; 181(1):294-302. PubMed ID: 22658484
[TBL] [Abstract][Full Text] [Related]
9. A Spontaneous Aggressive ERα+ Mammary Tumor Model Is Driven by Kras Activation.
Campbell KM; O'Leary KA; Rugowski DE; Mulligan WA; Barnell EK; Skidmore ZL; Krysiak K; Griffith M; Schuler LA; Griffith OL
Cell Rep; 2019 Aug; 28(6):1526-1537.e4. PubMed ID: 31390566
[TBL] [Abstract][Full Text] [Related]
10. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice.
Rose-Hellekant TA; Arendt LM; Schroeder MD; Gilchrist K; Sandgren EP; Schuler LA
Oncogene; 2003 Jul; 22(30):4664-74. PubMed ID: 12879011
[TBL] [Abstract][Full Text] [Related]
11. Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth.
Vomachka AJ; Pratt SL; Lockefeer JA; Horseman ND
Oncogene; 2000 Feb; 19(8):1077-84. PubMed ID: 10713693
[TBL] [Abstract][Full Text] [Related]
12. Prolactin involvement in breast cancer.
Vonderhaar BK
Endocr Relat Cancer; 1999 Sep; 6(3):389-404. PubMed ID: 10516853
[TBL] [Abstract][Full Text] [Related]
13. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice.
Wennbo H; Gebre-Medhin M; Gritli-Linde A; Ohlsson C; Isaksson OG; Törnell J
J Clin Invest; 1997 Dec; 100(11):2744-51. PubMed ID: 9389738
[TBL] [Abstract][Full Text] [Related]
14. Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas.
O'Leary KA; Rugowski DE; Sullivan R; Schuler LA
Oncogene; 2014 Jun; 33(23):3075-82. PubMed ID: 23873024
[TBL] [Abstract][Full Text] [Related]
15. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.
Gutzman JH; Miller KK; Schuler LA
J Steroid Biochem Mol Biol; 2004 Jan; 88(1):69-77. PubMed ID: 15026085
[TBL] [Abstract][Full Text] [Related]
16. Activation of the unliganded estrogen receptor by prolactin in breast cancer cells.
González L; Zambrano A; Lazaro-Trueba I; Lopéz E; González JJ; Martín-Pérez J; Aranda A
Oncogene; 2009 Mar; 28(10):1298-308. PubMed ID: 19169277
[TBL] [Abstract][Full Text] [Related]
17. Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma.
Manhès C; Kayser C; Bertheau P; Kelder B; Kopchick JJ; Kelly PA; Touraine P; Goffin V
J Endocrinol; 2006 Aug; 190(2):271-85. PubMed ID: 16899561
[TBL] [Abstract][Full Text] [Related]
18. Prolactin regulation of estrogen and progesterone receptors in normal and neoplastic mouse mammary tissue.
Koseki Y; Cole D; Matsuzawa A; Costlow ME
Jpn J Cancer Res; 1987 Oct; 78(10):1105-11. PubMed ID: 3119544
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptors alpha and beta in rat decidua cells: cell-specific expression and differential regulation by steroid hormones and prolactin.
Tessier C; Deb S; Prigent-Tessier A; Ferguson-Gottschall S; Gibori GB; Shiu RP; Gibori G
Endocrinology; 2000 Oct; 141(10):3842-51. PubMed ID: 11014241
[TBL] [Abstract][Full Text] [Related]
20. The role of prolactin in mammary carcinoma.
Clevenger CV; Furth PA; Hankinson SE; Schuler LA
Endocr Rev; 2003 Feb; 24(1):1-27. PubMed ID: 12588805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
